Stralem & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

Stralem & Co’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$13K	Hold	2,900	–	–	0.01%	61
2020 Q1	$11K	Buy	+2,900	New	+$11.9K	0.01%	59

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Stralem & Co's CPRX Position: Q2 2020 in Review

Stralem & Co held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2020 at 2,900 shares worth $13K. The position accounts for 0.01% of the portfolio, ranked #61.

Stralem & Co first reported a position in CPRX in Q1 2020 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold CPRX as of Q2 2020.

Stralem & Co held 2,900 shares of Catalyst Pharmaceutical worth $13K as of Q2 2020.
Stralem & Co left its Catalyst Pharmaceutical share count unchanged in Q2 2020.
Catalyst Pharmaceutical made up 0.01% of Stralem & Co's portfolio in Q2 2020, its #61 holding.
Stralem & Co first reported a position in Catalyst Pharmaceutical in Q1 2020 and has held it in 2 quarters since.
140 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.